close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,023.22 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
News headline image
2 Predictions for Eli Lilly in 2026 ↗
Can anything stop this high-flying drugmaker? 
Via The Motley Fool
News headline image
Here&#39;s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Why Eli Lilly (LLY) Stock Is Trading Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the stock benefited as investors rotated capital out of the volatile technology sector and into... 
Via StockStory
News headline image
Eli Lilly&#39;s Obesity Drug Dominance Still Underpriced By Market, Bank of America Says ↗
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership. 
Via Benzinga
News headline image
Eli Lilly Just Delivered Fantastic News to Investors ↗
Eli Lilly shares have climbed in the double digits this year. 
Via The Motley Fool
Eli Lilly Unveils New Data Showing Longer Survival With Breast Cancer Drug In Late-Stage Study ↗
Via Stocktwits
Eli Lilly’s New Obesity Treatment Shows Weight Loss Up To 71.2 Lbs, Reduces Pain In Trial ↗
Via Stocktwits
News headline image
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
2 Predictions for Novo Nordisk in 2026 ↗
The company's worst days might be behind it. 
Via The Motley Fool
News headline image
My Top 3 Healthcare Stocks to Buy in 2026 ↗
These habitual market beaters can pull it off again. 
Via The Motley Fool
News headline image
Eli Lilly Dividend Increase ↗
On Dec. 8, 2025, Eli Lilly increased its dividend by 15.33%, from $1.50 to $1.73 per share. The dividend is payable on March 10, 2026 to shareholders of record on Feb. 13, 2026. 
Via Talk Markets
News headline image
What Every Nucor Investor Should Know Before Buying ↗
New capacity is coming online in the domestic steel market. 
Via The Motley Fool
Topics Earnings
News headline image
Eli Lilly Leads Five Stocks Near Buy Points In Divided Market ↗
United Airlines and Urban Outfitters also are among 5 stocks showing strength. 
Via Investor's Business Daily
Topics Economy
News headline image
My Top 10 Stocks to Buy for 2026 ↗
These players are well-positioned to potentially gain next year -- and over time. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Market Bifurcation: Dow and S&P Soar to Records as Nasdaq Stumbles Amid Tech Reassessment
The U.S. stock market is currently experiencing a striking divergence in performance, with the venerable Dow Jones Industrial Average and the broad-based S&P 500 Index ascending to unprecedented record... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
New Eli Lilly Results Suggest Major Delay To Chemotherapy For Breast Cancer Patients ↗
Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients. 
Via Benzinga
News headline image
Eli Lilly Rises, Again, After EMA Recommends Mounjaro For Children As Young As 10 ↗
On Friday, Europe's drug regulator recommended extending the use of Eli Lilly's Mounjaro to children as young as 10. 
Via Investor's Business Daily
News headline image
The Best Turnaround Stock to Invest $1,000 in Right Now ↗
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term. 
Via The Motley Fool
News headline image
Dow Jones, Russell 2000 Hit Highs, Buoyed By Fed; Oracle, Broadcom Weigh On Techs: Weekly Review ↗
GE Vernova was a big winner. Eli Lilly and two biotechs released obesity drug data. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
News headline image
Dow Jones Industrial Average: An Intraday Record - What's Driving the Blue-Chip Surge?
The venerable Dow Jones Industrial Average (DJIA) has once again captured headlines, surging to unprecedented intraday record highs around December 2025. This remarkable ascent, which saw the blue-chip... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch ↗
FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from May. 
Via Benzinga
News headline image
Think Eli Lilly Is Expensive? This Metric Says Otherwise. ↗
The pharmaceutical stock can still deliver. 
Via The Motley Fool
News headline image
Why Novo Nordisk Stock Topped the Market on Thursday ↗
A proposed new federal law could provide some competitive guardrails for the company's most important product. 
Via The Motley Fool
News headline image
Market Soars to Unprecedented Heights: What Comes Next After Today's Record Run?
The financial markets roared to an emphatic close on December 11, 2025, with major indices shattering previous records in a session defined by widespread optimism and robust investor confidence. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Navigating Nuance: Tech Innovation, Healthcare Revival, and Energy's Evolving Landscape Shape Late 2025 Markets
As December 2025 unfolds, global financial markets are characterized by a delicate balance of cautious optimism and persistent uncertainty. A "Santa Claus rally" sentiment prevails, fueled by... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Value Stocks Stage a Comeback Bid Amidst Persistent Growth Dominance
The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Eli Lilly (LLY) Stock Is Up, What You Need To Know
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the morning session after the company announced highly positive Phase 3 trial results for its next-generation weight loss... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Eli Lilly's Retatrutide Soars: Unprecedented Trial Results Propel Pharma Giant, Ignite Obesity Market
Eli Lilly and Company (NYSE: LLY) has once again sent ripples through the pharmaceutical world with the announcement of groundbreaking Phase 3 trial results for its investigational obesity drug,... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Small-Cap Surge Signals Major Market Rebalancing: Investors Pivot from Tech to Broader Economy
Small-capitalization stocks are currently experiencing an unprecedented surge, with the benchmark Russell 2000 index shattering all-time records in early December 2025. This remarkable rally, which saw... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% ↗
The active ingredient retatrutide works on three gut hormones. 
Via Investor's Business Daily
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today